Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) EBT (2016 - 2025)

Historic EBT for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • NovaBay Pharmaceuticals' EBT rose 2624.78% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 million, marking a year-over-year increase of 5440.86%. This contributed to the annual value of -$7.2 million for FY2024, which is 2507.26% up from last year.
  • NovaBay Pharmaceuticals' EBT amounted to -$1.3 million in Q3 2025, which was up 2624.78% from -$228000.0 recorded in Q4 2024.
  • NovaBay Pharmaceuticals' 5-year EBT high stood at -$111000.0 for Q1 2022, and its period low was -$8.2 million during Q4 2022.
  • In the last 5 years, NovaBay Pharmaceuticals' EBT had a median value of -$1.7 million in 2023 and averaged -$1.9 million.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' EBT tumbled by 509367.09% in 2022, and later surged by 9444.99% in 2024.
  • NovaBay Pharmaceuticals' EBT (Quarter) stood at -$158000.0 in 2021, then crashed by 5093.67% to -$8.2 million in 2022, then soared by 49.94% to -$4.1 million in 2023, then skyrocketed by 94.45% to -$228000.0 in 2024, then plummeted by 450.88% to -$1.3 million in 2025.
  • Its EBT stands at -$1.3 million for Q3 2025, versus -$228000.0 for Q4 2024 and -$1.7 million for Q3 2024.